BMC Gastroenterology · 2021 · 11 citations · 10 references
Veterinary MedicineImmunologyPharmacotherapyImmunopathologyImmunotherapyInflammationCrohn Disease PharmacotherapyGastrointestinal InflammationImmune-mediated Inflammatory DiseasesInflammatory Bowel DiseaseInflammatory Disease PathologyInflammatory Disease PharmacotherapyAcute Inflammatory ResponseColonic PathologyDrug-induced ColitisInflammatory Bowel Disease ImmunopathogenesisInflammatory Bowel Disease PathologyInflammatory Bowel Disease TherapyInterleukin 17 InhibitionInterleukin-17 Inhibitors
BACKGROUND: Ixekizumab is monoclonal antibody targeted against interleukin-17 (IL-17) and has been approved for use in chronic plaque psoriasis. Despite its efficacy in treating psoriasis, concerns have been raised regarding Ixekizumab's potential to induce and exacerbate inflammatory bowel disease (IBD). CASE PRESENTATION: Here we report the new onset of severe drug-associated colitis with surgical complications in a 45-year-old male patient who was receiving Ixekizumab therapy for chronic plaque psoriasis. Review of the patient's colonic pathology demonstrated acute inflammatory changes with features of Crohn's disease. The patient remained disease-free 9-months following his hospitalization and cessation of Ixekizumab. CONCLUSIONS: This case raises suspicion for an association between Ixekizumab and IBD and calls on clinicians to have heightened awareness of potential risks before prescribing anti-IL-17 agents.
10
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Dermatology, Immunology +14
Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky et al. · Gut · 2012 · 1.5K citations · Full text
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 838 citations · Full text
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 806 citations · Full text